JP2025060686A5 - - Google Patents

Info

Publication number
JP2025060686A5
JP2025060686A5 JP2024218275A JP2024218275A JP2025060686A5 JP 2025060686 A5 JP2025060686 A5 JP 2025060686A5 JP 2024218275 A JP2024218275 A JP 2024218275A JP 2024218275 A JP2024218275 A JP 2024218275A JP 2025060686 A5 JP2025060686 A5 JP 2025060686A5
Authority
JP
Japan
Prior art keywords
composition
atrasentan
human subject
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024218275A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025060686A (ja
JP7821870B2 (ja
Filing date
Publication date
Priority claimed from JP2022537007A external-priority patent/JP7624995B2/ja
Application filed filed Critical
Publication of JP2025060686A publication Critical patent/JP2025060686A/ja
Publication of JP2025060686A5 publication Critical patent/JP2025060686A5/ja
Priority to JP2026010769A priority Critical patent/JP2026090302A/ja
Application granted granted Critical
Publication of JP7821870B2 publication Critical patent/JP7821870B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024218275A 2019-12-17 2024-12-12 アトラセンタンによるiga腎症を治療する方法 Active JP7821870B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026010769A JP2026090302A (ja) 2019-12-17 2026-01-26 アトラセンタンによるiga腎症を治療する方法

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US201962949115P 2019-12-17 2019-12-17
US62/949,115 2019-12-17
US202063005003P 2020-04-03 2020-04-03
US63/005,003 2020-04-03
US202063072699P 2020-08-31 2020-08-31
US63/072,699 2020-08-31
US202063084739P 2020-09-29 2020-09-29
US63/084,739 2020-09-29
US202063125205P 2020-12-14 2020-12-14
US63/125,205 2020-12-14
JP2022537007A JP7624995B2 (ja) 2019-12-17 2020-12-16 アトラセンタンによるiga腎症を治療する方法
PCT/US2020/065311 WO2021126977A1 (en) 2019-12-17 2020-12-16 Methods of treating iga nephropathy with atrasentan

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022537007A Division JP7624995B2 (ja) 2019-12-17 2020-12-16 アトラセンタンによるiga腎症を治療する方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026010769A Division JP2026090302A (ja) 2019-12-17 2026-01-26 アトラセンタンによるiga腎症を治療する方法

Publications (3)

Publication Number Publication Date
JP2025060686A JP2025060686A (ja) 2025-04-10
JP2025060686A5 true JP2025060686A5 (cg-RX-API-DMAC7.html) 2025-10-27
JP7821870B2 JP7821870B2 (ja) 2026-02-27

Family

ID=76478538

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2022537007A Active JP7624995B2 (ja) 2019-12-17 2020-12-16 アトラセンタンによるiga腎症を治療する方法
JP2024218275A Active JP7821870B2 (ja) 2019-12-17 2024-12-12 アトラセンタンによるiga腎症を治療する方法
JP2026010769A Pending JP2026090302A (ja) 2019-12-17 2026-01-26 アトラセンタンによるiga腎症を治療する方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022537007A Active JP7624995B2 (ja) 2019-12-17 2020-12-16 アトラセンタンによるiga腎症を治療する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026010769A Pending JP2026090302A (ja) 2019-12-17 2026-01-26 アトラセンタンによるiga腎症を治療する方法

Country Status (21)

Country Link
US (11) US20210353593A1 (cg-RX-API-DMAC7.html)
EP (2) EP4076652B1 (cg-RX-API-DMAC7.html)
JP (3) JP7624995B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230015874A (cg-RX-API-DMAC7.html)
CN (3) CN116327758A (cg-RX-API-DMAC7.html)
AU (1) AU2020404984A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022012075A2 (cg-RX-API-DMAC7.html)
CA (1) CA3161516A1 (cg-RX-API-DMAC7.html)
DK (1) DK4076652T3 (cg-RX-API-DMAC7.html)
FI (1) FI4076652T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20260121T1 (cg-RX-API-DMAC7.html)
IL (1) IL293921A (cg-RX-API-DMAC7.html)
LT (1) LT4076652T (cg-RX-API-DMAC7.html)
MX (1) MX2022007471A (cg-RX-API-DMAC7.html)
PH (1) PH12022551456A1 (cg-RX-API-DMAC7.html)
PL (1) PL4076652T3 (cg-RX-API-DMAC7.html)
PT (1) PT4076652T (cg-RX-API-DMAC7.html)
RS (1) RS67746B1 (cg-RX-API-DMAC7.html)
SI (1) SI4076652T1 (cg-RX-API-DMAC7.html)
TW (3) TW202615002A (cg-RX-API-DMAC7.html)
WO (1) WO2021126977A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20260121T1 (hr) 2019-12-17 2026-03-13 Chinook Therapeutics, Inc. Farmaceutski prihvatljiva sol atrasentana za uporabu u postupku za liječenje iga nefropatije
CN114910647A (zh) * 2022-05-07 2022-08-16 浙江大学 细丝蛋白-A-IgG抗体在制备检测血管内皮损伤试剂盒中的应用
WO2023220930A1 (en) * 2022-05-17 2023-11-23 Increvet, Inc. Veterinary pharmaceutical formulations cross-references to related applications
JP2025517355A (ja) * 2022-05-19 2025-06-05 チヌーク セラピューティクス,インコーポレイテッド アトラセンタンを用いた巣状分節性糸球体硬化症の治療方法
WO2024073672A1 (en) 2022-09-30 2024-04-04 Travere Therapeutics, Inc. Combination therapy with sparsentan and a sglt2 inhibitor for treating kidney diseases or disorders
US20260130933A1 (en) * 2022-10-05 2026-05-14 Daewoong Pharmaceutical Co., Ltd. Pharmaceutical composition for prevention or treatment of nephropathy and/or diabetes mellitus, comprising enavogliflozin
AU2023366516A1 (en) * 2022-10-28 2025-05-15 Aduro Biotech Holdings, Europe B.V. Treatment of iga nephropathy using an endothelin receptor antagonist and an april binding antibody
WO2024099272A1 (zh) * 2022-11-07 2024-05-16 信瑞诺医药(上海)有限公司 用于治疗IgA肾病的内皮素受体拮抗剂和糖皮质激素的组合
TW202604476A (zh) * 2024-06-21 2026-02-01 大陸商深圳信立泰藥業股份有限公司 內皮素a(eta)受體拮抗劑聯用sglt-2抑制劑的醫藥用途

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5236940A (en) 1988-12-15 1993-08-17 Rhone-Poulenc Sante Pharmaceutical compositions, 2-benzothiazolamine derivatives, and their preparation
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US7208517B1 (en) 1994-08-19 2007-04-24 Abbott Labortories Endothelin antagonists
US6946481B1 (en) 1994-08-19 2005-09-20 Abbott Laboratories Endothelin antagonists
US7365093B2 (en) 1994-08-19 2008-04-29 Abbott Laboratories Endothelin antagonists
US20020062121A1 (en) 1995-05-16 2002-05-23 Karl Tryggvason Perfusion apparatus and methods for pharmaceutical delivery
ES2259803T3 (es) 1996-02-13 2006-10-16 Abbott Laboratories Nuevos derivados de pirrolidina sustituidos con benzo-1,3-dioxolilo y benzofuranilo como antagonistas de endostelina.
US20040191774A1 (en) 2001-09-11 2004-09-30 Moskowitz David W Endothelin-1 promoter polymorphism
AU2003221042A1 (en) 2002-03-22 2003-10-08 Kissei Pharmaceutical Co., Ltd. Preventive or therapeutic agent for kidney disease
US20070134247A9 (en) 2002-04-12 2007-06-14 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
US20030229906A1 (en) 2002-04-15 2003-12-11 Gelman Irwin H. Methods and compositions for the treatment of disorders of HIV infection
US9388427B2 (en) 2002-12-02 2016-07-12 Biovec, Llc In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors
US7410483B2 (en) 2003-05-23 2008-08-12 Novare Surgical Systems, Inc. Hand-actuated device for remote manipulation of a grasping tool
WO2005120571A2 (en) 2004-06-07 2005-12-22 Ramot At Tel Aviv University Ltd. Method of passive immunization against disease or disorder characterized by amyloid aggregation with diminished risk of neuroinflammation
WO2006034234A1 (en) 2004-09-17 2006-03-30 Abbott Laboratories Crystalline form 3 of atrasentan hydrochloride
WO2006034084A1 (en) 2004-09-17 2006-03-30 Abbott Laboratories Crystalline form 2 of atrasentan hydrochloride
WO2006034085A1 (en) 2004-09-17 2006-03-30 Abbott Laboratories Crystalline form of atrasentan hydrochloride
US20060189675A1 (en) 2004-09-17 2006-08-24 Steve King Crystalline form of a drug
WO2007109244A2 (en) 2006-03-21 2007-09-27 Morehouse School Of Medicine Novel nanoparticles for delivery of active agents
KR20080108570A (ko) * 2006-03-27 2008-12-15 제넨테크, 인크. 신장 질환을 치료하는 방법
WO2007119214A2 (en) 2006-04-13 2007-10-25 Actelion Pharmaceuticals Ltd Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
ZA200902814B (en) 2007-01-16 2010-08-25 Musc Found For Res Dev Compositions and methods for diagnosing, treating, and preventing prostate conditions
CN101801936B (zh) 2007-07-31 2012-10-03 吉利德科罗拉多公司 安立生坦的代谢物和衍生物
CA2697057A1 (en) 2007-08-22 2009-02-26 Gilead Colorado, Inc. Therapy for complications of diabetes
US20120083421A1 (en) 2008-10-16 2012-04-05 The Trustees Of Columbia University In The City Of New York Use of urinary ngal to diagnose and monitor hiv-associated nephropathy (hivan)
WO2010114801A1 (en) 2009-03-31 2010-10-07 Ligand Pharmaceuticals Inc. Oral formulations of diphenylsulfonamide endothelin and angiotensin ii receptor agonists to treat elevated blood pressure and diabetic nephropathy
WO2011070049A1 (en) 2009-12-09 2011-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Endothelin inhibitors for the treatment of rapidly progressive glomerulonephritis
US9255931B2 (en) 2010-06-24 2016-02-09 Morehouse School Of Medicine Method and compositions for the treatment and detection of endothelin-1 related kidney diseases
CN103025670B (zh) 2010-07-28 2016-08-10 日本电气硝子株式会社 荧光体封入用毛细管的制造方法、荧光体封入用毛细管、波长变换部件和波长变换部件的制造方法
JP2016512201A (ja) * 2013-03-08 2016-04-25 アッヴィ・インコーポレイテッド 急性腎障害の治療方法
US9855245B2 (en) 2013-04-30 2018-01-02 Abbvie Inc. Methods for improving lipid profiles using atrasentan
PE20160221A1 (es) 2013-07-08 2016-05-22 Abbvie Inc Formas de dosificacion farmaceuticas estabilizadas que comprenden atrasentan
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
US8962675B1 (en) 2013-09-12 2015-02-24 Abbvie Inc. Atrasentan mandelate salts
WO2016073846A1 (en) * 2014-11-07 2016-05-12 Abbvie Inc. Methods of treating ckd using predictors of fluid retention
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
US20170014386A1 (en) 2015-07-16 2017-01-19 Abbvie, Inc. Treatment of Multidrug-Resistant Nephrotic Syndrome (MDR-NS) in Children
IL300122A (en) * 2015-11-18 2023-03-01 Merck Sharp ַ& Dohme Llc Substances that bind to PD1 and/or LAG3
CA3010593C (en) 2016-01-05 2024-02-13 University Of Leicester Methods for inhibiting fibrosis in a subject in need thereof
JP2019530713A (ja) * 2016-10-13 2019-10-24 レトロフィン, インコーポレイテッド 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物
IL294410B2 (en) 2016-11-23 2024-02-01 Chemocentryx Inc A method for the treatment of focal segmental tuberous sclerosis
MX386699B (es) 2017-10-11 2025-03-19 Chemocentryx Inc Tratamiento de glomerulosclerosis segmentaria focal con antagonistas ccr2
LT3716979T (lt) 2017-11-30 2025-07-10 Idorsia Pharmaceuticals Ltd 4-pirimidinsulfamido darinio derinys su sglt-2 inhibitoriumi, skirtas su endotelinu susijusių ligų gydymui
US20220304979A1 (en) 2019-12-17 2022-09-29 Chinook Therapeutics, Inc. Methods of reducing disease flares
HRP20260121T1 (hr) 2019-12-17 2026-03-13 Chinook Therapeutics, Inc. Farmaceutski prihvatljiva sol atrasentana za uporabu u postupku za liječenje iga nefropatije
US20230270718A1 (en) 2020-04-10 2023-08-31 Chinook Therapeutics, Inc. Methods of treating diabetic kidney disease
US20220243994A1 (en) 2021-02-04 2022-08-04 Northrop Grumman Systems Corporation Metal woodpile capillary wick

Similar Documents

Publication Publication Date Title
US10206919B2 (en) Use of levocetirizine and montelukast in the treatment of vasculitis
JP2024127897A5 (cg-RX-API-DMAC7.html)
RS66371B1 (sr) Nova upotreba kombinacije blokera angiotenzinskih receptora (arb) sa neutralnim inhibitorom endopeptidaze (nepi)
CN101420957B (zh) 炎症性肠病治疗药
WO2007149283B1 (en) Use of kw-3902 for achieving diuresis in patients with congestive heart failure and acute fluid overload
US20150320721A1 (en) Combinations of sglt 2 inhibitors and antihypertensive drugs
Dominguez Rieg et al. New functions and roles of the Na+-H+-exchanger NHE3
WO2015129750A1 (ja) 慢性腎臓病の進行抑制又は改善剤
Fenier et al. Enalapril improved renal function and proteinuria in chronic glomerulopathies
Varda et al. Diabetic kidney disease: from pathophysiology to treatment perspectives
EP3090744A1 (en) Pharmaceutical complex formulation comprising angiotensin ii receptor blocker and hmg-coa reductase inhibitor
EP2837380A1 (en) Lercanidipine hydrochloride and losartan potassium compound preparation and preparation method thereof
JP7668386B2 (ja) 1-(3-シアノ-1-イソプロピル-インドール-5-イル)ピラゾール-4-カルボン酸を含む薬学的組成物
US20110130421A1 (en) Methods and Compositions for the Treatment of Chronic Renal Hypertension
KR20230141662A (ko) 높은 혈중 요산 농도를 갖는 대상체의 만성 신장 질환의 예방 또는 치료를 위한 알로푸리놀, 페북소스타트 또는 이들의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물
CN116887843A (zh) 用于降低接受维持性透析的患者中的草酸盐/酯水平的组合物和方法
JPWO2011162390A1 (ja) 徐放性高血圧および腎機能障害治療剤
CN100453081C (zh) 用于治疗糖尿病性肾病的吡啶基亚磺酰氨基嘧啶
RU2741426C1 (ru) Никотинамид для лечения дислипидемии
US20150119401A1 (en) Compositions and Methods for the Treatment of Nasal Conditions
Ye et al. Nonsteroidal anti-inflammatory drug use and acute kidney injury in nephrectomies: a retrospective propensity score-matched cohort study
CN101014333A (zh) 包含洛索洛芬的口服组合物
Sahai et al. Pharmacology of the Therapeutic Approaches of Gout
WO2022225044A1 (ja) カリウム吸着薬を有効成分とする慢性腎不全(ckd)合併高カリウム血症患者の予後改善剤
Groothoff et al. Long-Term Nedosiran Safety and Efficacy in Primary Hyperoxaluria Type 1 (PH1): Interim Analysis of PHYOX3: TH-PO1128